|New Threads Only:|
|New Threads & Replies:|
Forum List » Value Ideas and Strategies|
Share and discuss value investing ideas and investing strategies.
Abbvie's Humira Continues to be a Powerful Catalyst for Growth
Posted by: Victor Selva (IP Logged)
Date: March 18, 2014 05:07PM
AbbVie Inc. (ABBV) is a research-based biopharmaceutical company that develops and markets therapies that address diseases. It also has a pipeline of medicines and company’s portfolio of proprietary products includes a line of adult and pediatric pharmaceuticals.
So let's take a look at this company and try to explain to investors the reasons this is an apparently appealing investment opportunity.
The key product is Humira, an anti-inflammatory product, an injectable biologic TNF (tumor necrosis factor) blocker treatment forrheumatoid arthritis (RA) and similar conditions. Humira sales increased to $10.7 billion in 2013 from $9.3 billion in 2012 and $7.9 billion in 2011.We estimate that Humira continues to see strong growth in the dermatology and gastroenterology markets, accounting for more than half of the global prescription drug market for rheumatoid arthritis. Humira has the potential to treat other diseases and is approved for many other uses, including juvenile idiopathic arthritis, psoriasis, ankylosing spondylitis, ulcerative colitis, Crohn's diseaseand axial spondyloarthritis. AbbVie's strategic objectives include expanding Humira's sales through greater penetration of emerging markets like China and Japan. The firm also plans to launch five significant new products in the next years that should help to boost sales.
Looking at the financials, the company has a strong balance sheet: good cash that allows it to reward current shareholders through dividend and share repurchases. Dividend-payment history affirms its commitment to maximize shareholder wealth. The company raised its quarterly dividend by 5% to $0.42 per share from $0.4.
The firm is currently Zacks Rank # 3 - Hold, and it also has a longer-term recommendation of “Neutral”. For investors looking for a better Zacks Rank there are no options, because all peer group -(Abbott Labs(ABT), Allergan Inc. (AGN), Astrazeneca PLC (AZN), Bristol-Myers (BMY), Johnson & Johnson (JNJ), Lilly Eli& Co. (LLY), Merck & Co. Inc. (MRK) and Novartis AG-ADR (NVS) have the same rank.
In terms of valuation, the stock sells at a trailing P/E of 20.3x, trading at a discount compared to an average of 29.5x for the industry. To use another metric, its price-to-book ratio of 18.5x indicates also a premium versus the industry average of 5.16x and the price-to-sales ratio of 4.4x is above the industry average of 11.35x.
Earnings per share (EPS) decreased in the most recent quarter compared to the same quarter a year ago. In the next graph we can see that it has demonstrated a positive trend and we include the stock price because EPS often lead the stock price movement.
Finally, I always like to see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the return on equity. Let´s compare the current ratio with competitors in the next table:
As we can see, the firm has a huge ratio and is higher than that shown by comps.
As outlined in this article, the firm´s ROE as well as the good cash flow and the stock price performance are demonstrating the improvement of the company´s strength.
I would recommend investors to consider adding the stock for their long-term portfolios. Hedge fund gurus have also been active in the company in fourth quarter 2013. Gurus like David Dreman (Trades, Portfolio), Steven Cohen (Trades, Portfolio), George Soros (Trades, Portfolio), Ken Fisher (Trades, Portfolio) and Murray Stahl (Trades, Portfolio) have also invested in it.
Disclosure: Victor Selva holds no position in any stocks mentioned.
Guru Discussed: David Dreman: Current Portfolio, Stock Picks
George Soros: Current Portfolio, Stock Picks
Stocks Discussed: AVVB, ABT, AZN, JNJ,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.